| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
136,550,000 |
| Market
Cap: |
23.51(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$117.67 - $177 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 558 |
| Guru Rank Value : 3.3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Natera is a diagnostics company. Co. operates one segment, the development and commercialization of molecular testing services, applying its proprietary technology in the fields of women's health, oncology and organ health. Co.'s product offerings include: Panorama Non-Invasive Prenatal Test, which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother; Vistara, which is a single-gene mutations screening test performed to identify single-gene disorders; and Horizon Carrier Screening, which determines carrier status for a number of severe genetic diseases that could be passed on to the carrier's children.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
99,289 |
274,246 |
1,070,214 |
2,674,696 |
| Total Sell Value |
$15,423,541 |
$41,660,205 |
$168,346,474 |
$288,630,755 |
| Total People Sold |
9 |
9 |
11 |
13 |
| Total Sell Transactions |
36 |
85 |
159 |
276 |
| End Date |
2025-06-15 |
2025-03-14 |
2024-09-13 |
2023-09-14 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Chapman Steven Leonard |
CEO AND PRESIDENT |
• • – |
2025-09-02 |
4 |
AS |
$165.44 |
$845,795 |
D/D |
(5,079) |
158,514 |
|
-0% |
|
| Moshkevich Solomon |
PRESIDENT, CLINICALDIAGNOSTICS |
• – – |
2025-09-02 |
4 |
AS |
$165.69 |
$499,865 |
D/D |
(3,000) |
120,859 |
|
-0% |
|
| Chapman Rowan E |
|
– • – |
2025-08-28 |
4 |
S |
$166.99 |
$459,223 |
D/D |
(2,750) |
6,015 |
|
-0% |
|
| Moshkevich Solomon |
PRESIDENT, CLINICALDIAGNOSTICS |
• – – |
2025-08-14 |
4 |
AS |
$155.42 |
$136,027 |
D/D |
(875) |
123,859 |
|
6% |
|
| Fesko John |
PRESIDENT, CHIEF BUS. OFFICER |
• – – |
2025-08-14 |
4 |
AS |
$155.30 |
$105,401 |
D/D |
(678) |
152,747 |
|
6% |
|
| Moshkevich Solomon |
PRESIDENT, CLINICALDIAGNOSTICS |
• – – |
2025-08-12 |
4 |
A |
$0.00 |
$0 |
D/D |
1,675 |
124,734 |
|
- |
|
| Fesko John |
PRESIDENT, CHIEF BUS. OFFICER |
• – – |
2025-08-12 |
4 |
A |
$0.00 |
$0 |
D/D |
1,675 |
153,425 |
|
- |
|
| Sheena Jonathan |
CO-FOUNDER |
– • – |
2025-08-11 |
4 |
AS |
$149.56 |
$461,012 |
I/I |
(3,000) |
34,282 |
|
7% |
|
| Sheena Jonathan |
CO-FOUNDER |
– • – |
2025-08-08 |
4 |
AS |
$156.40 |
$497,047 |
D/D |
(3,070) |
242,252 |
|
11% |
|
| Moshkevich Solomon |
PRESIDENT, CLINICALDIAGNOSTICS |
• – – |
2025-08-01 |
4 |
AS |
$132.45 |
$398,657 |
D/D |
(3,000) |
123,059 |
|
25% |
|
| Chapman Steven Leonard |
CEO AND PRESIDENT |
• • – |
2025-08-01 |
4 |
AS |
$132.43 |
$771,656 |
D/D |
(5,807) |
163,593 |
|
25% |
|
| Marcus Gail Boxer |
|
– • – |
2025-08-01 |
4 |
AS |
$132.73 |
$332,395 |
D/D |
(2,496) |
5,763 |
|
25% |
|
| Brophy Michael Burkes |
CHIEF FINANCIAL OFFICER |
• – – |
2025-07-29 |
4 |
AS |
$136.01 |
$418,397 |
D/D |
(3,045) |
65,430 |
|
24% |
|
| Sheena Jonathan |
CO-FOUNDER |
– • – |
2025-07-28 |
4 |
AS |
$139.81 |
$66,968 |
D/D |
(479) |
245,322 |
|
22% |
|
| Brophy Michael Burkes |
CHIEF FINANCIAL OFFICER |
• – – |
2025-07-28 |
4 |
AS |
$139.81 |
$282,273 |
D/D |
(2,019) |
68,475 |
|
22% |
|
| Moshkevich Solomon |
PRESIDENT, CLINICALDIAGNOSTICS |
• – – |
2025-07-28 |
4 |
AS |
$139.81 |
$308,417 |
D/D |
(2,206) |
126,059 |
|
22% |
|
| Rabinowitz Daniel |
SEC. AND CHIEF LEGAL OFFICER |
• – – |
2025-07-28 |
4 |
AS |
$139.81 |
$278,778 |
D/D |
(1,994) |
202,164 |
|
22% |
|
| Fesko John |
PRESIDENT, CHIEF BUS. OFFICER |
• – – |
2025-07-28 |
4 |
AS |
$139.81 |
$239,072 |
D/D |
(1,710) |
151,750 |
|
22% |
|
| Rabinowitz Matthew |
EXECUTIVE CHAIRMAN |
• • – |
2025-07-28 |
4 |
AS |
$139.81 |
$240,191 |
D/D |
(1,718) |
2,360,852 |
|
22% |
|
| Chapman Steven Leonard |
CEO AND PRESIDENT |
• • – |
2025-07-28 |
4 |
AS |
$139.81 |
$851,712 |
D/D |
(6,092) |
169,400 |
|
22% |
|
| Chapman Rowan E |
|
– • – |
2025-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
149 |
8,765 |
|
- |
|
| Brinkley Ruth W |
|
– • – |
2025-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
112 |
5,219 |
|
- |
|
| Baynes Roy D. |
|
– • – |
2025-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
108 |
18,266 |
|
- |
|
| Marcus Gail Boxer |
|
– • – |
2025-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
141 |
8,259 |
|
- |
|
| Bertagnolli Monica |
|
– • – |
2025-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
108 |
5,128 |
|
- |
|
1564 Records found
|
|
Page 1 of 63 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
3.65 (2.17%) 
